NCT00646880 - A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

August 31, 2003

Conditions

Urinary Bladder, Overactive

Interventions

DRUG

propiverine

Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.

DRUG

tolterodine PR

Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.

Trial Locations (1)

110-744

Pfizer Investigational Site, Seoul